Biotech startup Cue Health has secured a $13 million contract from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA), which will be used to speed the development and testing of a handheld molecular test that can detect the presence of the SARS-CoV-2 novel coronavirus that causes COVID-19.